GlassScriptPhysician profile
Tyler Lyman Marler
NPI 1255992905
$3,579.08
in general payments reported to CMS, 2019-2025
26 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $45.71 · 2021: $57.11 · 2022: $513 · 2023: $741 · 2024: $664 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,442.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $834.44 | 2022-2025 | |
| Novo Nordisk INC | $310.76 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $298.88 | 2022-2025 | Arexvy, Shingrix, Bexsero |
| Pfizer INC. | $274.62 | 2019-2025 | |
| Lilly USA, LLC | $254.54 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $253.89 | 2019-2025 | Airsupra, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.06 | 2022-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $157.58 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $123.69 | 2019-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Sunovion Pharmaceuticals INC. | $123.24 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $119.31 | 2019 | |
| Exact Sciences Corporation | $117.90 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $94.47 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $88.53 | 2022-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.35 | 2023-2025 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $42.70 | 2021 | |
| Optinose US, INC. | $37.11 | 2022 | |
| Novartis Pharmaceuticals Corporation | $36.00 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $35.81 | 2023-2025 | Livalo, Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.57 | 2025 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $24.09 | 2022 | |
| Esperion Therapeutics, INC. | $22.75 | 2024 | Nexletol |
| Allergan, INC. | $21.02 | 2020 | |
| Tris Pharma INC | $16.50 | 2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $14.86 | 2025 | Eliquis |
| Mannkind Corporation | $14.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Marler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.